Protagenic Therapeutics, Inc. (PTIX)
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
$2.65M
Dr. Garo H. Armen Ph.D.
New York, NY
Dec 18, 1996
-0.41
$-1.45
0.15
4.60
0.00%
-1.01
-0.01
0.64
0.00
4.01
-49.71%
-52.66%
Similar stocks (6)
Rezolute, Inc.
RZLT
Acrivon Therapeutics, Inc. Common Stock
ACRV
Eledon Pharmaceuticals, Inc.
ELDN
Aerovate Therapeutics, Inc.
AVTE
Tempest Therapeutics, Inc.
TPST
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (6)
Rezolute, Inc.
RZLT
Acrivon Therapeutics, Inc. Common Stock
ACRV
Eledon Pharmaceuticals, Inc.
ELDN
Aerovate Therapeutics, Inc.
AVTE
Tempest Therapeutics, Inc.
TPST
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%